Announcements Trials

Browse Landscape

Phase

Status

Unknown 1 Recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 26 Melanoma 25 Stomach Neoplasms 9 Neoplasms 8 Carcinoma, Renal Cell 7 Carcinoma, Hepatocellular 6 Squamous Cell Carcinoma of Head and Neck 5 Neoplasm Metastasis 5 Hodgkin Disease 5 Breast Neoplasms 5 Triple Negative Breast Neoplasms 4 Urinary Bladder Neoplasms 3 Prostatic Neoplasms 3 Pancreatic Neoplasms 3 Lung Neoplasms 3 Head and Neck Neoplasms 3 Esophageal Squamous Cell Carcinoma 3 Uveal Melanoma 2 Small Cell Lung Carcinoma 2 Sarcoma 2 Recurrence 2 Mesothelioma, Malignant 2 Lymphoma, B-Cell 2 Leukemia, Myeloid, Acute 2 Gastrointestinal Neoplasms 2 Esophageal Neoplasms 2 Carcinoma, Transitional Cell 2 Carcinoma, Merkel Cell 2 Carcinoma 2 Brain Neoplasms 2

Interventions

tislelizumab 1 spartalizumab 1 Nivolumab 1 Gemcitabine 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Muscle-Invasive Bladder Carcinoma × Nivolumab × Clear all

NCT04876313 2022-04-06

NURE-Combo

IRCCS San Raffaele

Phase 2 Unknown

Muscle-Invasive Bladder Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡